Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASPAR: Perioperative Spartalizumab + FLOT in Resectable Gastric Cancer
NCT04736485Phase 2Completed
- Sponsor
- Centre François Baclesse
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Centre François Baclesse. Started Jun 2021; status: completed.
02
Drugs
spartalizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04736485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736485.